probucol

Probucol (DH-581), an anti-hyperlipidemic drug, can lower the level of cholesterol in the bloodstream by increasing the LDL catabolic rate.

Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.

Probucoldithiobisphenol (DTBP) is a derivative of Probucol. It stimulates the production of heme oxygenase 1 (HO-1) and exhibits antioxidant properties. In the Apoe−/− mouse model, Probucol dithiobisphenol reduces aortic atherosclerotic lesions, and in a rabbit arterial injury model, it promotes arterial re-endothelialization and suppresses restenosis. This compound is orally active.

Probucol-[13C3] (Standard) is a reference standard of Probucol-[13C3] intended for quantitative analysis, quality control, and related biochemical research applications.

RC363 is an inhibitor of ferroptosis and a derivative of the antioxidant and hypocholesterolemic agent probucol .1It reduces 2,2-diphenyl-1-picrylhydrazyl radicals by approximately 40% in a cell-free assay when used at a concentration of 25 μM. RC363 prevents glutamate-induced toxicity in HT22 cultured hippocampal cells (IC50= 234.5 nM) but does not reduce oxidant levels in these cells. It increases the levels of glutathione peroxidase 1 (GPX1) and the activity of GPX in glutamate-challenged HT22 cells when used at a concentration of 3 μM. RC363 inhibits ferroptosis induced by the GPX4 inhibitor RSL3 in HT22 cells (IC50= 173.6 nM). 1.Bueno, D.C., Canto, R.F.S., de Souza, V., et al.New probucol analogues inhibit ferroptosis, improve mitochondrial parameters, and induce glutathione peroxidase in HT22 cellsMol. Neurobiol.57(8)3273-3290(2020)

1. Tiliroside (Tribuloside) shows anticarcinogenic activity. 2. Tiliroside shows hepatoprotective activity. 3. Tiliroside shows antioxidant and anti-inflammatory activity, can inhibit neuroinflammation in neurodegenerative disorders. 4. Tiliroside has anti-diabetic effect, are at least partially mediated through inhibitory effects on carbohydrate digestion and glucose uptake in the gastrointestinal tract. 5. Tiliroside and gnaphaliin are antioxidants against in vitro Cu(2+)-induced LDL oxidation in the same order of magnitude compared to that of the reference drug, probucol. 6. Tiliroside enhances fatty acid oxidation via the enhancement adiponectin signaling associated with the activation of both AMP-activated protein kinase and peroxisome proliferator-activated receptor α and ameliorates obesity-induced metabolic disorders.

Tiliroside (Standard) is a reference standard for research and analytical applications involving Tiliroside. Tiliroside (Tribuloside) exhibits anticarcinogenic activity. Tiliroside demonstrates hepatoprotective activity. Tiliroside exhibits antioxidant and anti-inflammatory activity and can inhibit neuroinflammation in neurodegenerative disorder models. Tiliroside demonstrates anti-diabetic effects that are at least partially mediated through inhibitory effects on carbohydrate digestion and glucose uptake in the gastrointestinal tract. Tiliroside and gnaphaliin function as antioxidants against in vitro Cu(2+)-induced LDL oxidation in the same order of magnitude compared with the reference compound probucol. Tiliroside enhances fatty acid oxidation through enhancement of adiponectin signaling associated with activation of both AMP-activated protein kinase and peroxisome proliferator-activated receptor α and ameliorates obesity-induced metabolic disorders. Tiliroside (Standard) is therefore extensively applicable to metabolic, oxidative stress, inflammation, and natural product-based biomedical research.

Isosalvianolic acid C exhibits more potent activity than probucol except for salvianolic acid F .